Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Operations: 2019-2025

Historic Cash from Operations for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$207.3 million.

  • Revolution Medicines' Cash from Operations fell 58.96% to -$207.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$761.8 million, marking a year-over-year decrease of 41.15%. This contributed to the annual value of -$557.4 million for FY2024, which is 59.01% down from last year.
  • Latest data reveals that Revolution Medicines reported Cash from Operations of -$207.3 million as of Q3 2025, which was up 6.51% from -$221.8 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Cash from Operations peaked at -$34.1 million during Q2 2021, and registered a low of -$221.8 million during Q2 2025.
  • Over the past 3 years, Revolution Medicines' median Cash from Operations value was -$130.4 million (recorded in 2024), while the average stood at -$139.2 million.
  • Data for Revolution Medicines' Cash from Operations shows a maximum YoY plummeted of 157.34% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Revolution Medicines' Cash from Operations stood at -$39.3 million in 2021, then slumped by 57.36% to -$61.8 million in 2022, then plummeted by 95.12% to -$120.6 million in 2023, then fell by 14.70% to -$138.3 million in 2024, then crashed by 58.96% to -$207.3 million in 2025.
  • Its Cash from Operations stands at -$207.3 million for Q3 2025, versus -$221.8 million for Q2 2025 and -$194.4 million for Q1 2025.